65,437 trials
Neutropenia · Breast Cancer
Primary: Duration of Severe Neutropenia (DSN) in Cycle 1 — 0.31; 0.39 Days — p=< 0.0001
Various Advanced Cancer
Primary: Overall Survival (OS) in Participants With Tumor Cell PD-L1 — 13.70; 15.44; 9.07 Months — p=0.0010
Ann Arbor Stage I Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue · Ann Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue · Extranodal Marginal Zone Lymphoma
Primary: Relapse-free Survival (RFS) — 83 months
Recurrent Plasma Cell Myeloma · Refractory Plasma Cell Myeloma
Primary: ORR Evidenced by Confirmed Response Rate, Defined as Number of Patients With Partial Response or Better by International Myeloma Working Group (IMWG) Criteria Divided by…
Partial Thickness Supraspinatus Tendon Tear · Full Thickness Supraspinatus Tendon Tear
Primary: Change in Tendon Thickness — 1.7; 2.6; 1.2; 1.2 millimeters
Achondroplasia
Primary: Change From Baseline in Annualized Growth Velocity (AGV) at Week 52 — 1.71; 0.13 cm/year — p=< 0.0001
Acute Pain
Primary: Change in Numerical Rating Scale of Pain (NRS) Before Treatment to 60 Minutes After Treatment — 6.2; 5.4 units on a scale — p=0.08
HIV · Tuberculosis · Hypertension
Primary: Cumulative HIV Incidence — 0.77; 0.81 cumulative events per 100 persons
Veno-occlusive Disease
Primary: Veno-occlusive Disease (VOD)-Free Survival by Day +30 Post-Hematopoietic Stem Cell Transplant (HSCT) Per the Independent Endpoint Adjudication Committee (EPAC) — 66.8…
Osteogenesis Imperfecta, Type I · Osteogenesis Imperfecta Type III · Osteogenesis Imperfecta Type IV
Primary: Change From Baseline in Radial Trabecular Volumetric Bone Mineral Density (Tr vBMD) at Month 12 — 1.004; 0.993; 0.992 ratio — p=0.644
Induced Abortion
Primary: Initial Cervical Dilation — 11.7; 10.9 mm
HIV · Pre-exposure Prophylaxis
Primary: Change in Intention to Use PrEP Score — 0.19; 0.00; 0.57; -0.09 score on a scale — p=0.85
Metastatic Carcinoma in the Liver · Recurrent Colorectal Carcinoma · Stage IV Colorectal Cancer AJCC v7
Primary: Change in Tumor-infiltrating Lymphocytes (TILs) in the Colorectal Cancer Lesions — 7.25 fold change — p=0.046
Sturge-Weber Syndrome
Primary: Number of Seizures Per Month — 33.5; 30.0; 3.0; 0.5 Seizures per month
Chronic Plaque Psoriasis · Moderate to Severe Plaque Psoriasis
Primary: Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response at Week 16 — 86.2; 47.2 percentage of participants — p=<0.001